Renalytix FY EPS $(0.56) Beats $(0.57) Estimate, Sales $3.40M Miss $3.62M Estimate
Portfolio Pulse from Benzinga Newsdesk
Renalytix (NASDAQ:RNLX) reported a smaller than expected quarterly loss of $(0.56) per share, beating the analyst consensus estimate of $(0.57) by 1.75 percent. However, the company's quarterly sales of $3.40 million missed the analyst consensus estimate of $3.62 million by 5.99 percent.
September 28, 2023 | 10:07 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Renalytix's EPS beat estimates but sales missed, which could lead to mixed market reactions.
Renalytix's earnings per share (EPS) beat the analyst consensus estimate, which is generally a positive signal for investors. However, the company's sales missed the estimate, which could be a negative signal. The mixed results could lead to a neutral or mixed market reaction in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100